Centessa Short Term Debt vs Total Current Assets Analysis

CNTA Stock

USD 18.08 1.08 6.35%

Centessa Pharmaceuticals financial indicator trend analysis is way more than just evaluating Centessa Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Centessa Pharmaceuticals is a good investment. Please check the relationship between Centessa Pharmaceuticals Short Term Debt and its Total Current Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Centessa Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Short Term Debt vs Total Current Assets

Short Term Debt vs Total Current Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Centessa Pharmaceuticals Short Term Debt account and Total Current Assets. At this time, the significance of the direction appears to have strong relationship.

The correlation between Centessa Pharmaceuticals' Short Term Debt and Total Current Assets is 0.78. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of Centessa Pharmaceuticals PLC, assuming nothing else is changed. The correlation between historical values of Centessa Pharmaceuticals' Short Term Debt and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of Centessa Pharmaceuticals PLC are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Short Term Debt i.e., Centessa Pharmaceuticals' Short Term Debt and Total Current Assets go up and down completely randomly.

Correlation Coefficient

0.78

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Short Term Debt

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Most indicators from Centessa Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Centessa Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Centessa Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

At present, Centessa Pharmaceuticals' Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 758.2 M, whereas Selling General Administrative is forecasted to decline to about 33.9 M.

	2021	2023	2024 (projected)
Depreciation And Amortization	34.0K	813.1K	853.8K
Interest Income	244K	10.5M	11.0M

Depreciation And Amortization Interest Income

Centessa Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Other Current Liab	Net Tangible Assets	Current Deferred Revenue	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Non Current Liabilities Total	Inventory	Deferred Long Term Liab	Net Invested Capital
Total Assets		0.95	0.88	1.0	-0.83	0.8	0.99	0.36	0.5	0.95	0.97	1.0	0.79	0.88	0.99	-0.39	-0.88	0.89	0.94	0.91	0.8	0.81	0.99	-0.76	-0.39	1.0
Short Long Term Debt Total	0.95		0.97	0.93	-0.94	0.84	0.92	0.41	0.68	1.0	0.99	0.94	0.85	0.98	0.98	-0.51	-0.72	0.96	0.81	0.98	0.68	0.94	0.95	-0.66	-0.51	0.95
Total Current Liabilities	0.88	0.97		0.84	-0.96	0.87	0.83	0.51	0.71	0.98	0.95	0.86	0.88	0.99	0.92	-0.53	-0.62	0.99	0.71	0.99	0.67	0.97	0.88	-0.67	-0.53	0.89
Total Stockholder Equity	1.0	0.93	0.84		-0.8	0.76	1.0	0.3	0.45	0.93	0.94	1.0	0.74	0.85	0.97	-0.35	-0.91	0.86	0.96	0.88	0.82	0.77	0.99	-0.78	-0.35	0.99
Retained Earnings	-0.83	-0.94	-0.96	-0.8		-0.79	-0.78	-0.46	-0.86	-0.94	-0.91	-0.81	-0.77	-0.98	-0.9	0.74	0.49	-0.96	-0.61	-0.97	-0.51	-0.97	-0.86	0.51	0.74	-0.86
Long Term Debt	0.8	0.84	0.87	0.76	-0.79		0.77	0.83	0.58	0.83	0.9	0.79	0.99	0.81	0.83	-0.46	-0.61	0.8	0.69	0.82	0.58	0.78	0.81	-0.56	-0.46	0.81
Cash And Short Term Investments	0.99	0.92	0.83	1.0	-0.78	0.77		0.34	0.43	0.92	0.94	1.0	0.75	0.83	0.96	-0.33	-0.92	0.84	0.96	0.87	0.83	0.74	0.99	-0.79	-0.33	0.99
Common Stock Shares Outstanding	0.36	0.41	0.51	0.3	-0.46	0.83	0.34		0.42	0.4	0.52	0.35	0.79	0.42	0.4	-0.4	-0.21	0.42	0.26	0.42	0.2	0.41	0.4	-0.2	-0.4	0.39
Other Current Assets	0.5	0.68	0.71	0.45	-0.86	0.58	0.43	0.42		0.66	0.64	0.48	0.53	0.76	0.63	-0.94	-0.04	0.7	0.18	0.72	0.01	0.83	0.55	-0.01	-0.94	0.55
Other Stockholder Equity	0.95	1.0	0.98	0.93	-0.94	0.83	0.92	0.4	0.66		0.98	0.94	0.84	0.98	0.98	-0.49	-0.73	0.97	0.81	0.99	0.72	0.94	0.95	-0.7	-0.49	0.95
Total Liab	0.97	0.99	0.95	0.94	-0.91	0.9	0.94	0.52	0.64	0.98		0.96	0.9	0.94	0.99	-0.5	-0.76	0.93	0.84	0.95	0.7	0.9	0.96	-0.66	-0.5	0.97
Total Current Assets	1.0	0.94	0.86	1.0	-0.81	0.79	1.0	0.35	0.48	0.94	0.96		0.78	0.87	0.98	-0.37	-0.89	0.87	0.95	0.89	0.8	0.78	0.99	-0.76	-0.37	0.99
Short Term Debt	0.79	0.85	0.88	0.74	-0.77	0.99	0.75	0.79	0.53	0.84	0.9	0.78		0.82	0.82	-0.36	-0.62	0.8	0.69	0.82	0.6	0.79	0.78	-0.58	-0.36	0.79
Other Current Liab	0.88	0.98	0.99	0.85	-0.98	0.81	0.83	0.42	0.76	0.98	0.94	0.87	0.82		0.93	-0.6	-0.59	0.99	0.7	1.0	0.63	0.98	0.89	-0.62	-0.6	0.89
Net Tangible Assets	0.99	0.98	0.92	0.97	-0.9	0.83	0.96	0.4	0.63	0.98	0.99	0.98	0.82	0.93		-0.49	-0.8	0.92	0.87	0.94	0.71	0.88	0.98	-0.67	-0.49	0.99
Current Deferred Revenue	-0.39	-0.51	-0.53	-0.35	0.74	-0.46	-0.33	-0.4	-0.94	-0.49	-0.5	-0.37	-0.36	-0.6	-0.49		-0.05	-0.55	-0.08	-0.56	0.1	-0.64	-0.46	-0.1	1.0	-0.45
Net Debt	-0.88	-0.72	-0.62	-0.91	0.49	-0.61	-0.92	-0.21	-0.04	-0.73	-0.76	-0.89	-0.62	-0.59	-0.8	-0.05		-0.63	-0.99	-0.65	-0.92	-0.47	-0.85	0.87	-0.05	-0.85
Accounts Payable	0.89	0.96	0.99	0.86	-0.96	0.8	0.84	0.42	0.7	0.97	0.93	0.87	0.8	0.99	0.92	-0.55	-0.63		0.73	1.0	0.7	0.96	0.9	-0.71	-0.55	0.9
Cash	0.94	0.81	0.71	0.96	-0.61	0.69	0.96	0.26	0.18	0.81	0.84	0.95	0.69	0.7	0.87	-0.08	-0.99	0.73		0.75	0.91	0.58	0.92	-0.87	-0.08	0.92
Non Current Assets Total	0.91	0.98	0.99	0.88	-0.97	0.82	0.87	0.42	0.72	0.99	0.95	0.89	0.82	1.0	0.94	-0.56	-0.65	1.0	0.75		0.69	0.96	0.92	-0.69	-0.56	0.92
Non Currrent Assets Other	0.8	0.68	0.67	0.82	-0.51	0.58	0.83	0.2	0.01	0.72	0.7	0.8	0.6	0.63	0.71	0.1	-0.92	0.7	0.91	0.69		0.5	0.78	-0.99	0.1	0.78
Net Receivables	0.81	0.94	0.97	0.77	-0.97	0.78	0.74	0.41	0.83	0.94	0.9	0.78	0.79	0.98	0.88	-0.64	-0.47	0.96	0.58	0.96	0.5		0.81	-0.5	-0.64	0.82
Non Current Liabilities Total	0.99	0.95	0.88	0.99	-0.86	0.81	0.99	0.4	0.55	0.95	0.96	0.99	0.78	0.89	0.98	-0.46	-0.85	0.9	0.92	0.92	0.78	0.81		-0.74	-0.46	1.0
Inventory	-0.76	-0.66	-0.67	-0.78	0.51	-0.56	-0.79	-0.2	-0.01	-0.7	-0.66	-0.76	-0.58	-0.62	-0.67	-0.1	0.87	-0.71	-0.87	-0.69	-0.99	-0.5	-0.74		-0.1	-0.74
Deferred Long Term Liab	-0.39	-0.51	-0.53	-0.35	0.74	-0.46	-0.33	-0.4	-0.94	-0.49	-0.5	-0.37	-0.36	-0.6	-0.49	1.0	-0.05	-0.55	-0.08	-0.56	0.1	-0.64	-0.46	-0.1		-0.45
Net Invested Capital	1.0	0.95	0.89	0.99	-0.86	0.81	0.99	0.39	0.55	0.95	0.97	0.99	0.79	0.89	0.99	-0.45	-0.85	0.9	0.92	0.92	0.78	0.82	1.0	-0.74	-0.45

Click cells to compare fundamentals

Centessa Pharmaceuticals Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
MSFT	Microsoft

When determining whether Centessa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Centessa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Centessa Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Centessa Pharmaceuticals Plc Stock:

How To Invest In Centessa

Details

Is Centessa Stock a good investment?

Details

What is Centessa Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Centessa Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Centessa Pharmaceuticals. If investors know Centessa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Centessa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.55)

Revenue Per Share

0.068

Return On Assets

(0.25)

Return On Equity

(0.56)

The market value of Centessa Pharmaceuticals is measured differently than its book value, which is the value of Centessa that is recorded on the company's balance sheet. Investors also form their own opinion of Centessa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Centessa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Centessa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Centessa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Centessa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Centessa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Centessa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Centessa Short Term Debt vs Total Current Assets Analysis

Short Term Debt vs Total Current Assets

Short Term Debt vs Total Current Assets Correlation Analysis

Correlation Coefficient

Short Term Debt

Total Current Assets

Centessa Pharmaceuticals fundamental ratios Correlations

Centessa Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Other Stockholder Equity	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity

Inventory	- 0.99	Non Currrent Assets Other
Cash	- 0.99	Net Debt
Other Current Liab	- 0.98	Retained Earnings
Net Receivables	- 0.97	Retained Earnings
Non Current Assets Total	- 0.97	Retained Earnings
Accounts Payable	- 0.96	Retained Earnings